Written and maintained by CASRAI Editorial Board
Last updated
CiteAb is an independent citation-ranked search engine designed to help life science researchers find and validate research antibodies and biochemical reagents. Rather than ranking search results according to vendor listing fees or paid sponsorships, the platform ranks products algorithmically by the number of times they have been cited in peer-reviewed scientific literature. In modern biomedical research, selecting unvalidated reagents is a primary cause of experimental irreproducibility and wasted grant funding; CiteAb addresses this challenge by tying catalog entries directly to published experimental evidence.
What CiteAb Is
CiteAb is a bibliographic and reagent discovery database established to resolve reproducibility challenges associated with research antibodies. Selecting the correct reagent for biological assays—such as Western blotting, immunohistochemistry, flow cytometry, or immunoprecipitation—requires confirming that an antibody specifically binds its target antigen in a defined experimental context. A reagent that works robustly in a denatured Western blot may fail completely or produce non-specific background in an intact tissue section or flow cytometry panel, as outlined in our guide on primary and secondary antibodies.
Unlike general web search engines, which frequently prioritize reagent suppliers with commercial advertising budgets, CiteAb collects catalog information from suppliers and links each product to citations extracted from peer-reviewed journal articles. Researchers use CiteAb to inspect how many times a given antibody clone or catalog number has been published, which experimental applications were tested, which host species were examined, and which specific publications contain supporting validation data.
Who Runs CiteAb and What It Covers
CiteAb originated in 2013 as an academic project conceived by Dr. Andrew Chalmers, a senior lecturer in the Department of Biology and Biochemistry at the University of Bath. The technical infrastructure was built in partnership with Bath alumni David Kelly and Adam Pope through the technology firm Storm Consultancy. CiteAb spun out from the University of Bath in January 2014 as CiteAb Limited. Initial funding was provided by the UK Engineering and Physical Sciences Research Council (EPSRC) Knowledge Transfer Account, the Higher Education Funding Council for England (HEFCE) Innovation Fund, and the University of Bath Enterprise and Knowledge Exploitation team.
CiteAb indexes commercial antibody manufacturers, specialized biotech distributors, and non-profit or grant-funded academic repositories. Its coverage includes:
- Commercial Suppliers: Catalogs from global vendors (including Abcam, Bio-Rad, Cell Signaling Technology, Santa Cruz Biotechnology, and Proteintech) are indexed, allowing cross-vendor comparison for the same target antigen.
- Academic and Non-Profit Repositories: Repositories funded by public agencies such as the National Institutes of Health (NIH) are indexed alongside commercial products. Key non-profit suppliers include the Developmental Studies Hybridoma Bank (DSHB) at the University of Iowa, the UC Davis NeuroMab facility, and the Zebrafish International Resource Center (ZIRC) at the University of Oregon.
- Expanded Reagents: In addition to monoclonal, polyclonal, and recombinant primary antibodies, CiteAb indexes secondary antibodies, biochemicals, assay kits, and experimental models.
How to Search and Evaluate Reagents on CiteAb
Navigating CiteAb requires structured querying and careful appraisal of citation records. Researchers can follow this seven-step protocol to identify and verify suitable reagents:
- Enter Specific Target Identifiers: In the primary search field, enter the target protein name, official gene symbol, clone identifier, supplier catalog code, or immunogen sequence. Using standardized gene or protein nomenclature reduces ambiguous results from legacy aliases.
- Examine the Results Summary Table: Search results display a ranked list of matched reagents sorted descending by total verified citation count. The summary table shows the antibody name, catalog code, supplier name, host species, species reactivity, experimental applications, and citation count.
- Distinguish Literature Citations from Supplier Claims: CiteAb visually differentiates experimental validation sources: applications and species reactivities confirmed by published, peer-reviewed journal papers are rendered in red text, whereas applications merely claimed or recommended by the supplier’s technical datasheet appear in standard black text. Prioritize reagents supported by red-coded literature citations.
- Apply Faceted Methodological Filters: Refine candidate reagents using the left-hand navigation panel. Filter by experimental application (e.g., Western blot, IHC, IF, Flow Cytometry, ELISA, or ChIP), host species (such as rabbit, mouse, or goat), target species reactivity (e.g., human, mouse, rat), clonality (monoclonal, recombinant monoclonal, or polyclonal), and conjugate status.
- Inspect Individual Antibody Record Pages: Click a selected reagent row to open its full detail page. This view aggregates technical specifications, supplier links, and a chronological listing of citing peer-reviewed publications accompanied by direct links to paper records.
- Verify Experimental Controls in Primary Literature: Do not rely solely on citation volume. Open the cited publications to confirm that the authors validated the antibody using rigorous biological controls, such as CRISPR knockout cell lines, siRNA knockdown, or antigen pre-adsorption.
- Record Reagent Identifiers for Publication: When selecting an antibody, record its catalog number, batch or lot number, supplier name, and unique Research Resource Identifier (RRID) to ensure compliance with author guidelines and data management mandates. For definitions of persistent identifiers, consult the CASRAI RRID dictionary term.
Strengths and Limits of Citation-Based Reagent Discovery
Evaluating reagents via publication citations provides clear advantages over commercial advertising, but researchers must remain aware of methodological limitations.
Strengths
- Algorithmic Impartiality: Search rankings reflect verified peer-reviewed citations rather than vendor placement fees. Suppliers cannot purchase top placement in standard search results.
- Transparent Validation Traceability: Direct links between catalog entries and scientific literature allow investigators to inspect real-world experimental protocols, dilution ratios, and published staining patterns.
- Multi-Source Aggregation: Centralizing commercial and academic hybridoma repositories in a single interface saves time during literature reviews and experimental design.
Limits
- Citation Lag for Novel and Recombinant Reagents: Newly synthesized recombinant antibodies or recently introduced targets lack historical citations. Because CiteAb ranks by total citation count, superior modern reagents may rank below older, less specific polyclonal lots simply because they are new to the market.
- Historical Citation Momentum: An antibody that was widely adopted early in biomedical literature can accumulate hundreds of citations despite known cross-reactivity or batch variability issues. High citation volume indicates widespread adoption, not necessarily flawless specificity.
- Publication Quality Variation: While a citation demonstrates that an antibody was utilized in a peer-reviewed study, it does not guarantee that the citing authors properly authenticated the reagent with knockout or negative controls.
Alternatives to CiteAb
Depending on whether a laboratory prioritizes citation metrics, independent user reviews, or formal identity registry indexing, several complementary platforms are available to researchers:
| Platform | Host / Operator | Primary Ranking and Curation Model | Validation Evidence Base | Access and Cost Model |
|---|---|---|---|---|
| CiteAb | CiteAb Limited (University of Bath spinout) | Algorithmic ranking by peer-reviewed literature citations | Extracted citations and publication links | Free search for researchers; commercial data services |
| Antibodypedia | Academic consortium / LabLife | Validation scores based on standardized criteria | User-submitted validation reports, blot images, and scoring | Free public portal for academic and industrial researchers |
| Biocompare | CompareNetworks | Commercial directory with sponsored listings and keyword search | Product specifications, vendor datasheets, and user reviews | Free search for researchers; sponsored supplier listings |
| Antibody Registry | Center for Research in Biological Systems (UCSD) | Persistent identifier registry assigning unique RRIDs | Curated catalog matching across vendors and published papers | Free open-access community infrastructure |
Frequently Asked Questions
How does CiteAb rank antibody search results?
CiteAb ranks search results primarily by the total number of peer-reviewed scientific citations identified for each reagent. Antibodies with the greatest number of published citations appear at the top of the search table by default.
Can antibody manufacturers pay to improve their search ranking on CiteAb?
No. CiteAb operates on an impartial ranking model where search results are determined by verified academic citations. Reagent suppliers cannot pay to boost a product’s ranking position in standard search queries.
What does red text versus black text mean in CiteAb search results?
Red text indicates that an experimental application or species reactivity has been demonstrated in a peer-reviewed scientific publication indexed by CiteAb. Black text represents technical recommendations and claims provided directly by the supplier’s catalog datasheet.
How should researchers cite antibodies identified through CiteAb?
When publishing research, investigators should cite the primary manufacturer, the specific catalog number, the lot or batch number, and the unique Research Resource Identifier (RRID). Researchers can also cite the primary validation papers identified through CiteAb to document reagent provenance.
How can researchers find newly developed antibodies that have zero citations?
Researchers can filter search results by specific supplier or clonality, or browse newly cataloged entries. CiteAb lists antibodies that currently lack citations so that scientists can discover new products and contribute citation data as experiments are published.
Sources
- Helsby MA, Leader PM, Fenn JR, Gulsen T, Bryant C, Doughton G, Sharpe B, Whitley P, Caunt CJ, James K, Pope AD, Kelly DH, Chalmers AD. CiteAb: a searchable antibody database that ranks antibodies by the number of times they have been cited. BMC Cell Biology 15, 6 (2014). doi:10.1186/1471-2121-15-6. PMCID: PMC3928599. Date read: 2026-11-07.
- University of Bath. Antibody search engine spins out from University of Bath. Press Release, published 11 February 2014, updated 21 December 2018. https://www.bath.ac.uk/announcements/antibody-search-engine-spins-out-from-university-of-bath/. Date read: 2026-11-07.
- University of Bath. University researcher launches antibody search engine. Press Release, published 11 March 2013, updated 21 December 2018. https://www.bath.ac.uk/announcements/university-researcher-launches-antibody-search-engine/. Date read: 2026-11-07.
